The swamp is busy this weekend trying there level

The swamp is busy this weekend trying there level best to tamp down FDA expectations going into EOP2. What we do know is B for OM has shown statistically significant therapeutic benefit by decreasing the incidence of SOM. B oral rinse has low systemic absorption, FDA should love this aspect imo. We are going against a hugely unmet debilitating disease so for crying out loud why wouldn't FDA get excited about it as well as our licensing partner.

http://www.ipharminc.com/press-release/2018/9...treatments